Literature DB >> 9130628

Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis.

H Shiono1, Y Fujii, M Okumura, Y Takeuchi, M Inoue, H Matsuda.   

Abstract

The most unusual characteristic of myasthenia gravis (MG) is that the thymus has germinal centers (GC). Cultured thymic lymphocytes from MG patients spontaneously produce anti-acetylcholine receptor antibodies, indicating that autoreactive B cells have escaped negative selection. To investigate the underlying mechanism, we examined the expression of the apoptosis-related protein Bcl-2 in GC B cells (defined as CD19+ CD38+ cells) in the thymus in 14 MG patients using three-color flow cytometry. GC in MG patients did not show the normal down-regulation of Bcl-2 (the frequency of Bcl-2+ GC B cells in the MG thymus and in control tonsils 54.3 +/- 16.2% versus 20.6 +/- 8.0%; mean +/- SD. p < 0.0001). In contrast, Bcl-2 in GC in the mediastinal lymph nodes from four patients was down-regulated to a relatively normal level. Using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method to detect DNA fragmentation in situ, the frequency of TUNEL+ cells in GC in the MG thymus was lower than in control tonsils. These results suggest that autoreactive B cells which normally undergo apoptosis in GC may survive because of Bcl-2 up-regulation in this unusual location.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130628     DOI: 10.1002/eji.1830270402

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers.

Authors:  M P Armengol; M Juan; A Lucas-Martín; M T Fernández-Figueras; D Jaraquemada; T Gallart; R Pujol-Borrell
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 2.  Ectopic lymphoid organogenesis: a fast track for autoimmunity.

Authors:  C M Weyand; P J Kurtin; J J Goronzy
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Inclusion of the transcervical approach in video-assisted thoracoscopic extended thymectomy (VATET) for myasthenia gravis: a prospective trial.

Authors:  N Shigemura; H Shiono; M Inoue; M Minami; M Ohta; M Okumura; H Matsuda
Journal:  Surg Endosc       Date:  2006-06-22       Impact factor: 4.584

Review 4.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells.

Authors:  M S Bynoe; C M Grimaldi; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 6.  Biological implications of thymectomy for myasthenia gravis.

Authors:  Meinoshin Okumura; Masayoshi Inoue; Yoshihisa Kadota; Akio Hayashi; Toshiteru Tokunaga; Takashi Kusu; Noriyoshi Sawabata; Hiroyuki Shiono
Journal:  Surg Today       Date:  2010-01-28       Impact factor: 2.549

7.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

8.  Analysis of serum miRNA profiles of myasthenia gravis patients.

Authors:  Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.